APA (7th ed.) Citation

Wang, H., Wang, G., Li, T., Zhang, P., Mao, Z., Luo, H., . . . Huang, L. (2025). Efficacy and safety of a novel CD19, CD22 dual-targeted fully human loop bi-CAR-T for the treatment of relapsed/refractory B cell non-Hodgkin lymphoma. Journal of Translational Medicine, 23(1), 1. https://doi.org/10.1186/s12967-025-06567-3

Chicago Style (17th ed.) Citation

Wang, Hanyu, et al. "Efficacy and Safety of a Novel CD19, CD22 Dual-targeted Fully Human Loop Bi-CAR-T for the Treatment of Relapsed/refractory B Cell Non-Hodgkin Lymphoma." Journal of Translational Medicine 23, no. 1 (2025): 1. https://doi.org/10.1186/s12967-025-06567-3.

MLA (9th ed.) Citation

Wang, Hanyu, et al. "Efficacy and Safety of a Novel CD19, CD22 Dual-targeted Fully Human Loop Bi-CAR-T for the Treatment of Relapsed/refractory B Cell Non-Hodgkin Lymphoma." Journal of Translational Medicine, vol. 23, no. 1, 2025, p. 1, https://doi.org/10.1186/s12967-025-06567-3.